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KESAN EKSTRAK MITRAGYNA SPECIOSA KE ATAS ENZIM 
METABOLISME DRUG 
 
ABSTRAK  
  
 
Daun M. speciosa (ketum) telah digunakan secara tradisional di Malaysia dan Thailand 
untuk meredakan ketagihan candu dan sebagai pengganti candu di saat ketiadaan candu. 
Daun M. speciosa telah disalahgunakan oleh penagih dadah kerana terdapatnya beberapa 
alkaloid (terutamanya mitraginina) dari tumbuhan ini yang mempunyai kesan seakan 
candu dan kokain. Hal ini membawa kepada larangan penggunaan daun M. speciosa di 
Malaysia sejak tahun 2004 kerana pengambilan M. speciosa telah dianggap membawa 
kepada penyalahgunaan dadah lain seperti ganja dan heroin. Dalam kajian ini, kesan in 
vitro dan in vivo ekstrak metanol, akues dan alkaloid total M speciosa ke atas enzim 
metabolisme drug, iaitu sitokrom P450 (CYP450), UDP-glukuronosil transferase (UGT) 
dan glutation S-transferase (GST) telah dinilai di dalam fraksi sitosol dan mikrosom hati 
tikus. Aminopirina, p-nitrofenol (pNP) dan 1-kloro-2,4-dinitrobenzena (CDNB) masing-
masing digunakan sebagai substrat prob dalam esei enzim aminopirina N-demetilase 
(APND), UDP-glukuronosil transferase (UGT) dan glutation S-transferase (GST). 
Tambahan pula, terbitan pelbagai lusiferina digunakan sebagai substrat prob untuk 
menguji secara in vitro lima isofom utama CYP450 manusia di dalam sistem 
bakulosom. Selanjutnya, mitraginina juga diuji secara in vitro untuk melihat 
kemungkinan ia menghalang aktiviti APND, isofom CYP450 manusia, UGT dan GST. 
Oleh kerana berbagai penerbitan telah menunjukkan kemampuan tumbuh-tumbuhan 
ubat untuk memodulasi aktiviti enzim metabolisme drug adalah kerana kandungan 
antioksidannya, maka kandungan fenol total, kandungan flavonoid total dan kapasiti 
memusnahkan DPPH untuk ketiga-tiga ekstrak M. speciosa turut dinilai. Penilaian 
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aktiviti enzim dan kajian antioksidan dijalankan menggunakan kaedah penyerapan dan 
luminesen. Daripada ketiga-tiga ekstrak M. speciosa, ekstrak metanol adalah yang 
paling berkesan dalam merencat aktiviti APND, UGT dan GST secara in vitro diikuti 
oleh ekstrak akues dan alkaloid total. Walaubagaimanapun, nilai IC50 hanya boleh 
diperolehi untuk ekstrak metanol sahaja di dalam kajian perencatan APND 
(595.30±30.78 µg/mL) dan tidak di dalam kajian yang lain. Ini adalah disebabkan oleh 
peratusan perencatan enzim kurang dari 70%. Selanjutnya, ekstrak metanol M. speciosa 
juga menunjukkan kandungan flavonoid total tertinggi (90.29±2.34 mg CE/g ekstrak) 
dan nilai IC50 terendah untuk kapasiti memusnahkan DPPH (24.89±1.57 mg/mL). 
Mitraginina sebaliknya menunjukkan kurang perencatan pada aktiviti APND dan UGT 
tetapi tidak merencat aktiviti GST. Tambahan lagi, isofom CYP2D6 adalah yang paling 
direncat oleh  ekstrak metanol, akues dan alkaloid total M. speciosa, dan mitraginina 
dengan nilai IC50 masing-masing  0.72±0.10, 29.72±4.02, 0.21±0.03 dan 5.99±1.02 
(15.02±2.56 µM) mg/mL. Berbeza dengan kajian secara in vitro, rawatan oral ke atas 
tikus jantan Sprague Dawley selama 14 hari dengan 50, 100 dan 200 mg/kg ekstrak 
metanol dan akues, dan dengan 5, 10 dan 20 mg /kg ekstrak alkaloid total menunjukkan 
peningkatan ke atas aktiviti APND dan aktiviti UGT tetapi tidak pada aktiviti GST. 
Daripada hasil kajian ini, boleh disimpulkan bahawa mekanisme modulasi yang berbeza 
ke atas enzim metabolisme drug  mungkin terlibat yang menyebabkan perbezaan 
keputusan di dalam kajian  in vitro dan in vivo.  
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EFFECTS OF MITRAGYNA SPECIOSA EXTRACTS ON DRUG 
METABOLIZING ENZYMES 
 
ABSTRACT 
 
 
M. speciosa (ketum) leaves have been employed traditionally in Malaysia and Thailand 
to wean opium addiction and as a substitute for opium when opium is unavailable. M. 
speciosa leaves have been abused by drug addicts since some of the alkaloids (mainly 
mitragynine) from the plant possess opiate and cocaine like effects. These bring to its 
prohibition in Malaysia in 2004 since consumption of M. speciosa leaves has been 
perceived to lead to the abuse of other drugs such as cannabis and heroin. In the current 
study, the in vitro and in vivo effects of M. speciosa methanolic, aqueous and total 
alkaloid extracts on drug metabolizing enzymes, namely cytochrome P450 (CYP450), 
UDP-glucuronosyl transferase (UGT) and glutathione S-transferase (GST) had been 
evaluated in rat liver cytosolic fraction and microsomes. Aminopyrine, p-nitrophenol 
(pNP) and 1-chloro-2,4-dinitrobenzene (CDNB) were employed as probe substrates in 
aminopyrine N-demethylase (APND), UDP-glucuronosyl transferase (UGT) and 
glutathione S-transferase (GST) enzyme assays respectively. In addition, various 
luciferin derivatives were employed as probe substrates to assay five main human 
CYP450 isoforms in baculosomes systems in vitro. Furthermore, mitragynine was also 
tested in vitro for its likelihood to inhibit APND, human CYP450 isoforms, UGT and 
GST activity. The total phenolics content, total flavonoids content and DPPH 
scavenging capacity for the three M. speciosa extracts were also evaluated.  This is 
because various publications have implicated the antioxidant content of medicinal herbs 
to be responsible for the modulation of drug metabolizing enzymes activites.  The 
assessment of the enzyme activity and antioxidant study were conducted using 
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absorbance and luminescent methods. Out of the three M. speciosa extracts, the 
methanolic extract is the most effective in inhibiting the APND, UGT and GST activity 
in vitro followed by aqueous and total alkaloid extracts. However, IC50 value could only 
be derived for methanolic extract in APND study (595.30±30.78 µg/mL) and not in 
other studies. This is due to the enzyme percentage inhibitions were less than 70%. In 
addition, M. speciosa methanolic extract exhibited the highest total phenolic content 
(97.48±2.86 mg GAE/g extract), the highest total flavonoids content (90.29±2.34 mg 
CE/g extract) and the lowest IC50 value for the DPPH antioxidant scavenging capacity 
(24.89±1.57 µg/mL). Mitragynine on the other hand, showed low inhibition on APND 
and UGT activities but had no inhibition on GST activity. Additionally, CYP2D6 
isoform is the most inhibited by M. speciosa methanolic, aqueous and total alkaloid 
extracts, and mitragynine with respective IC50 value of 0.72±0.10, 29.72±4.02, 
0.21±0.03 and 5.99±1.02 (15.02±2.56 µM). In contrast to the in vitro study, oral 
treatment of male Sprague Dawley rats for 14 days with 50, 100 and 200 mg/kg of 
methanolic and aqueous extracts, and with 5, 10 and 20 mg/kg of total alkaloid extract 
showed increment of APND and UGT activities, but not GST activity. It can be 
concluded that different mechanisms of modulation of drug metabolizing enzymes might 
have taken place leading to the disparity in the results between in vitro and in vivo study. 
 
 
 
CHAPTER ONE 
INTRODUCTION 
 
Many of the clinically important drug-drug interactions result from perturbations of drug 
metabolism, involving either induction or inhibition of drug metabolizing enzymes, 
principally the cytochrome P450s (Woolf, 1999). The usage of herbal medicines as an 
alternative way to treat multiple ailments and diseases has been a phenomenon 
worldwide; Malaysia is not exceptional (Aziz & Tey, 2009). Herbal medicines are 
deemed to be safer for human than conventional medicines owing to public belief that 
herbal medicines are not synthetic chemicals; since it is more natural (Lynch & Berry, 
2007). However, this is not the case, in view of the fact that herbs contains various type 
of chemicals, although natural, have potentials to interfere with pharmacokinetic 
properties of other drugs (Venkataramanan, et al., 2006). The pharmacokinetics 
interactions of herbal medicines with other medicines could occur when there are 
alterations in absorption, metabolism, distribution and excretion of drugs (Zhou, Koh, 
Gao, Gong, & Lee, 2004). Alteration of drug metabolism by interference with herbal 
medicines is significantly important. This is because, most of the reported clinical 
adverse drug interactions were due to the induction or inhibition of drug metabolizing 
enzymes, specifically cytochrome P450s (CYP450), UDP-glucuronosyl transferase 
(UGT) and glutathione S-transfrease (GST) (Woolf, 1999). Mitragyna speciosa has been 
employed as an herbal medicine by natives in Southeast Asia particularly in Malaysia 
and Thailand to wean opium addiction and as a substitute for opium when opium is 
unavailable (Reanmongkol, Keawpradub, & Sawangjaroen, 2007; Suwanlert, 1975; 
Tsuchiya, et al., 2002). Pharmacological effects of M. speciosa extract are largely due to 
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the main principle alkaloid, mitragynine which acts mainly on mu and delta opioid 
receptors in in vivo and in vitro studies and possess analgesic effect (Takayama, et al., 
2002; Yamamoto, et al., 1999). Most of the studies on M. speciosa were focused on the 
chemical and medicinal aspects and there is no study done on the effects of of this plant 
extracts and its principle alkaloid on drug metabolizing enzymes. Knowledge of the 
modulation of drug metabolizing enzymes by M. speciosa extracts and mitragynine is a 
fundamental requirement to the success of potential drug candidates (Plant, 2004), as 
poorly understood safety features could lead to unpredicted failures in clinical trial.  
With this in view, it is essential to have some sort of procedures to screen M. speciosa 
extracts and mitragynine against drug metabolizing enzymes, thus, avoiding the serious 
and significant clinical herb-drug interactions. Herein, in this study, M. speciosa 
methanolic, aqueous and total alkaloid extracts and its principle alkaloid, mitragynine 
were investigated for their effects on aminopyrine N-demethylation, UDP-glucuronic 
acid conjugation and glutathione conjugation in vitro. Additionally, further efforts were 
taken by using five main human CYP450 isoforms, in order to see the potential 
inhibition of M. speciosa extracts and mitragynine on those isoforms in vitro.  Besides in 
vitro study, in vivo study was also conducted by treating the male Sprague-Dawley rats 
for 14 days with M. speciosa methanolic, aqueous and total alkaloid extracts by oral 
route, in order to see the potential modulation on aminopyrine N-demethylation, UDP-
glucuronic acid conjugation and glutathione conjugation. Furthermore, the antioxidant 
properties such as total phenolics content and total flavonoids content were also assessed 
to see the involvement of these phytochemicals on modulating drug metabolizing 
enzymes. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Herbal Medicines 
Recently, herbal medicines have been gaining popularity worldwide as food 
supplements and to treat illnesses as they are perceived to be safer and more natural than 
allopathic medicines (Lynch & Berry, 2007). Accordingly, it is estimated that 60% of 
the world’s population use herbal medicines entirely for medication (Farnsworth, 1994). 
Besides, the herbal medicines industry in Malaysia is growing at more than 15-20% per 
year, faster than the general economy. Indeed, annual sales for traditional herbal 
medicines had increased from USD385 million to USD1.29 billion from 2000 to 2005 
and is expected to be worth USD2.5 billion by 2010 (Aziz & Tey, 2009). Herbs by 
WHO (2000) definition are crude plant materials that include leaves, flowers, fruit, seed, 
stems, wood, bark, roots, rhizomes or other plant parts which might be completely 
fragmented or powdered. Conversely, herbal medicines are defined as a plant-derived 
material or preparation with therapeutic or other human health benefits which contains 
either raw or processed ingredients from one or more plants (WHO, 2000). The 
documented early usage of herbal medicines to treat illnesses can be traced back 5000 
years ago during Sumerian era, however, archeological evidence suggest even earlier 
usage of herbal medicines (Raskin, et al., 2002). Additionally, traditional use of herbal 
medicines might refer to the long historical use with well establish and widely 
acknowledged safety and effectiveness, and may be accepted by national authorities 
(WHO, 2000). The systems to utilize traditional herbal medicines vary rather than 
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uniform across different countries or cultures due to the localized philosophy, religion 
and the availability of the medicinal herbs in a specific region. This is exemplified by 
the ancient Traditional Chinese Medicines (TCM) originated from China, ‘ayurveda’ 
from India and ‘jamu’ from Indonesia. Herbal medicines have been demonstrated to 
protect against many diseases such as diabetes mellitus, cancer, neurodegenerative, 
gastric, ulcers, ischemic reperfusion, arthritis and inflammatory diseases (Arancibia-
Avila, et al., 2008). These beneficial effects have been attributed to the various 
antioxidants such as polyphenols, ascorbic acid, carotenoids, and tocopherols which are 
present in the herbal medicines (Du, Li, Ma, & Liang, 2009). In addition, polyphenols 
have powerful antioxidant activities by scavenging a wide range of reactive species, 
including hydroxyl radicals, peroxyl radicals, hypochlorous acid and superoxide radical 
(Harnafi & Amrani, 2008). 
 
There are estimated at least 300,000 species of higher plants worldwide and 
approximately 10,000 of this plants have a documented medicinal purpose (McChesney, 
Venkataraman, & Henri, 2007). Thirty five thousands of the species can be encountered 
in South East Asia and out of 8,000 species are found in Malaysia. The above data 
suggest that a vast number of plants biodiversity have yet to be explored for its 
medicinal values. In Malaysia, herbal medicines that have been used for generations for 
various health benefits are Eurycoma longifolia, Orthosiphon stamineus, Andrographis 
paniculata and Centella asiatica. These medicinal herbs have undergone extensive 
studies either locally or internationally for its medicinal benefits and will be reviewed 
further in this chapter.  
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Eurycoma longifolia is a traditional herb popular in Malaysia and other Southeast 
Asian countries for its aphrodisiac properties. The plant is called as ‘Malaysian ginseng’ 
whereby a tea prepared by cooking 20–50 g of roots for about half an hour and taken as 
a health tonic and anti-stress remedy (Zanoli, Zavatti, Montanari, & Baraldi, 2009). 
Traditionally known as ‘tongkat Ali’, a decoction of the roots is drunk to enhance the 
virility and sexual prowess (Ong & Nordiana, 1999). It also can be consumed on a daily 
basis for preventing or treating erectile dysfunction in men (Low & Tan, 2007). The 
ability of the root extract to modulate sexual behaviour could be ascribed to its 
testosterone enhancing property (Ang & Lee, 2002). Zanoli et al. (2009) have recently 
demonstrated that the oral administration of the root powder was able to improve sexual 
performance in sluggish rats and partially restore the normal sexual behaviour in 
impotent rats. Besides its main indication for enhancing sexual health, E. longifolia also 
have been proven scientifically to show antimalarial activity (Ang, Chan, & Mak, 1995). 
Indeed, before scientific evidence proved that E. longifolia posses’ antimalarial activity, 
Malaysian aborigines (orang asli) have been consuming E. longifolia extract once they 
have febrifuge and malaria (Ang, et al., 1995). Several active compounds responsible for 
the aphrodisiac and antimalarial properties such as eurycomanone, eurycomanol and 
eurycomalactone have been isolated from this plant (Chan, Lee, Sam, & Han, 1989).  
 
Orthosiphon stamineus, known as “misai kucing” in Malaysia and as ‘Java tea’ 
in Indonesia, is one of the most popular medicinal plants in Southeast Asia in treating 
various forms of illnesses including kidney stone and other urinary tract diseases, 
diabetes mellitus, hypertension, tonsillitis, arteriosclerosis, rheumatism and menstrual 
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disorders (Awale, Tezuka, Banskota, Adnyana, & Kadota, 2003a; Awale, Tezuka, 
Banskota, & Kadota, 2003b; Awale, et al., 2001; Tezuka, et al., 2000). It has been 
introduced into the Western countries since early 20th century (Pan, et al., 2011). In 
Malaysia, it is mainly use to treat stone disease and gout while in Indonesia it is mainly 
used as diuretics (Arafat, et al., 2008). There are four main polyphenolic compounds that 
have been determined in O. stamineus namely rosmarinic acid, caffeic acid, sinensetin 
and eupatorin (Tezuka, et al., 2000). These polyphenolic compounds and caffeic acid are 
belived to responsible in the diuretic and uricosuric effects in rats (Olah, Radu, 
Mogosan, Hanganu, & Gocan, 2003). Besides, the methanolic extract of this plant have 
shown the inhibitory activity on nitric oxide production in macrophage like cells (Awale, 
et al., 2003a; Awale, et al., 2003b).  
 
Andrographis paniculata, also known as ‘‘king of bitters” due to its extremely 
bitter taste is a medicinal herb widely distributed in South India, Sri Lanka, China and 
Malaysia (Lii, Tsai, Yang, & Chen, 2008). In Malaysia it is known as ‘hempedu bumi’ 
while in Indonesia it is called ‘sambiroto’. It is traditionally employed for centuries in 
Asia as a folklore remedy for a wide spectrum of ailments. In Scandinavia, an extract of 
A. paniculata called ‘kan jang’, has been used extensively for the past 20 years for the 
treatment of the common cold (Pekthong, et al., 2008). The herb has been shown to have 
various pharmacological activities, including anti-inflammatory (Sheeja, Shihab, & 
Kuttan, 2006), anticancer (Cheung, et al., 2005), immuno-stimulatory (Iruretagoneya, et 
al., 2005), antiviral (Wiart, et al., 2005), hepatoprotective (Singha, Roy, & Dey, 2007) 
and antidiabetic (Reyes, et al., 2006). The main active phytochemical in A. paniculata is 
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the diterpene lactone, andrographolide (Zhang & Tan, 1997). In recent times, 
Chandrasekaran et al. (2010) have reported that the extract of A. paniculata containing at 
least seven phytochemical constituents with significant anti-inflammatory and anti-
allergic properties in the animal models investigated. This study provides a rationale for 
its applications in traditional medicine as anti-inflammatory and antipyretic drug 
(Chandrasekaran, Gupta, & Agarwal, 2010).  
 
Centella asiatica also known as ‘pegaga’ in Malaysia is an herb that is 
commonly eaten fresh as a vegetable (salad), especially among the Malay communities 
(Hamid, Shah, Muse, & Mohamed, 2002). It is also blended into a drink and used as a 
cooling drink. This medicinal herb is native to countries like Sri Lanka, Madagascar, 
South Africa and Malaysia. Fresh extracts of this plant have been used by the people of 
Java and the Malay Peninsula for many years, as both topical and internal agents for 
healing of wounds (Hamid, et al., 2002). In an Indian system of medicine, ‘ayurveda’, 
this plant is used in the management of central nervous system, skin and gastrointestinal 
disorder (Subathra, Shila, Devi, & Panneerselvam, 2005). A number of studies have 
demonstrated the effectiveness of C. asiatica triterpenes, in particular the glycoside 
asiaticoside, in promoting wound healing (Macquart, et al., 1999). The medicinal 
properties of C. asiatica have been ascribed to three triterpenoids: asiatic acid, 
asiaticoside and madecassic acid (Inamdar, Yeole, Ghogare, & de Souza, 1996). Asiatic 
acid has been showed to induce apoptosis and cell cycle arrest in different types of 
cancer (Park, et al., 2007). On the other hand, asiaticoside shows promising wound 
healing activity in normal as well as in diabetic animals and warrants more detailed 
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experimental and clinical studies (Wijeweera, Arnason, Koszyckib, & Merali, 2006). It 
also provides a rationale for the use of C. asiatica preparations in the Indian traditional 
system of medicine to promote wound healing (Shukla, et al., 1999). 
 
Malaysia is blessed with an abundance of various medicinal plants and Malaysia 
is among the world’s 12 mega biodiversity-rich countries, in terms of number of plant 
species (Institute for Medical Research, 2002). Despite the current preoccupation with 
combinatorial and chemical synthesis as a vehicle to discover and develop new drugs, 
the contributions of plant-derived natural product for curing, treating and preventing 
diseases are still large (Simmond, 2003). Herbs as non-mobile organism produce a large 
number of secondary metabolites that serve to repel or discourage the use of the plant by 
insects, microorganisms, animals and men. These secondary metabolites with complex 
chemical and highly varied structures which are unlikely and uneconomical to be 
synthesized in the laboratories might be used for new drugs discovery and development 
(Patrick, 2001). Indeed, herbs have been natural combinational chemist for unimaginable 
decades and have been selecting products from that combinational library that suitable 
for interacting specifically with biological target molecules, for examples, membrane 
receptor or an active site of enzymes (McChesney, et al., 2007). This is emphasized by 
the fact that 25% of the total numbers of clinically used drugs were derived from plants 
and this is include the classical drugs atropine from Atropa belladonna, codeine and 
morphine (Papaver somniferum), digoxin (Digitalis spp.), and quinine (Cinchona spp.) 
(Phillipson, 2007). Herbs therefore remain as promising sources of new drugs in drug 
discovery and development research and will continue to be so. One successful example 
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of a clinical drug that derived from plant with sales worth more than USD150 million in 
1993 (McChesney, et al., 2007) is paclitaxel (Taxol®) from the bark of mature trees 
Taxus brevifolia. Historically, a journey of paclitaxel was started in 1962 through the 
National Cancer Institute (NCI) program for evaluation of plant preparations for 
anticancer activity. The T. brevifolia bark extract exhibited a strong cytotoxic activity on 
in vitro cancer cells in 1964 (McChesney, et al., 2007). In 1971, the structure of 
paclitaxel was elucidated (Wani, Taylor, Wall, Coggon, & McPhail, 1971) and in 1977, 
extensive studies on animals’ model of cancer were conducted and the positive 
outcomes lead paclitaxel to enter clinical trial. Finally, in 1992 paclitaxel was approved 
for utilization in the treatment of refractory ovarian cancer. Besides as sources for new 
drugs, natural product from herb could also act as a template for development of new 
chemicals entity with enhanced efficacy, high potentcy, less side effect and perhaps 
distinct pharmacological activity from the parent compound. Other successful drugs 
candidates that derived from herbs and currently use clinically are anticancer drug, 
vincristine from Catharantus roseus, antimalarial drug, artemisinin (Artemisia annua) 
and ibogaine (Tabernanthe iboga) for opiate addiction treatment.  
 
2.2 Mitragyna speciosa 
2.2.1 Plant Description 
Mitragyna speciosa Korth (M. speciosa) is found in tropical and subtropical regions of 
Asia and is categorized in family Rubiaceae. M. speciosa is an evergreen and non-
seasonal plant that is arborial in character and may grow to a height of 30 meters 
(Shellard, 1974). This species grows heavily in damp areas rich with humus and is 
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sensitive towards drought and extreme cold (Shellard, 1974). M. speciosa can be 
characterized by the globular yellow flowering head each containing up to 120 florets 
(Shellard, 1974). The genus was given the name Mitragyna by Korthals because the 
shape of the stigmas in the species he examined resembled a bishop's mitre (Shellard, 
1974). Two types of M. speciosa can be distinguished based on the colour of veins in the 
dark green leaf, either red or green (Chittrakarn, Keawpradub, Sawangjaroen, 
Kansenalak, & Janchawee, 2010). In Thailand, M. speciosa is normally known as 
‘kratom’, ‘kakuam’, ‘ithang’ and ‘thom’ (Suwanlert, 1975). It is a tree native to 
Malaysia where it is mostly called ‘ketum’ or ‘biak-biak’. In Malaysia, they can be 
found particularly in northern states of peninsular Malaysia and Selangor (Burkill, 1935; 
Houghton & Said, 1986).  
 Figure 2.1: Mitragyna speciosa Flower and Leaf. (Image adapted from 
http://img.alibaba.com/photo/105022189/Kratom_mitragyna_speciosa_red_vein_super_
kratom_medicine.jpg. Assessed on 14th April 2011.)  
 
2.2.2 Traditional Applications 
Mitragyna speciosa has been employed as an herbal medicine by natives in Southeast 
Asia particularly in Malaysia and Thailand for decades; however, the exact time for it to 
begin serving as an herbal medicine cannot be dated. Main traditional application of M. 
speciosa is to wean opium addiction and as a substitute for opium when opium is 
unavailable (Reanmongkol, Keawpradub, & Sawangjaroen, 2007; Suwanlert, 1975; 
Tsuchiya, et al., 2002). Additionally, it is often used in its own right as a narcotic drug 
11 
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(Chittrakarn, et al., 2010). Burkill (1935) reported that Thai people, mainly labourer and 
farmer, have been using M. speciosa to give them a pleasurable effect since it has coca-
like stimulant ability at lower dose to combat fatigue and enhance tolerance for hard 
work under intense sunlight and has opium-like properties at higher dose (Grewal, 1932; 
Suwanlert, 1975). There is an observation in 1836 that Malay people consumed M. 
speciosa as an opium substitute (Jansen & Prast, 1988). Besides being used as a tonic to 
boost energy, it is often used to treat diarrhea or intestinal infections by amoeba and 
protozoa (Chuakul, Temsiririrkkul, Saralamp, & Paonil, 1995). A small number of M. 
speciosa users consumed it as a tonic to prolong sexual intercourse. Other traditional 
applications of M. speciosa as an alternative treatment is to alleviate and treat pain, 
muscle ache and fatigue, hypertension, cough, fever, malaria, worm infestation and 
diabetes (Chan, Pakiam, & Rahim, 2005; Jansen & Prast, 1988; Shellard, 1974).  
 
2.2.3 Phytochemistry of Mitragyna speciosa 
Phytochemistry studies of the constituents of Mitragyna speciosa have been reported 
and over 22 alkaloids have been isolated from M. speciosa leaves (Shellard, 1974). 
Mitragynine, an indole alkaloid was found to be the major constituent of M. speciosa 
leaves, accounting for about half of the total alkaloid contents (Sukrong, et al., 2007) 
and is believed to contribute to the pharmacological effects of M. speciosa. Historically, 
mitragynine was firstly isolated in 1907 by Hooper and was repeated by Field in 1921 
who named the alkaloid mitragynine (Shellard, 1974). The structure of mitragynine was 
determined with X-ray crystallography by Zacharias, Rosenstein and Jeffrey in 1964 
(Shellard, 1974). Chemically known as 9-methoxy-corynantheidine (C23H2ON2O4) with 
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molecular weight of 398.50, mitragynine is soluble in chloroform, alcohol and acetic 
acid. Its structure resembles yohimbine (Babu, Mccurdy, & Boyer, 2008) and is very 
stable with a melting point between 102 and 106°C and a boiling point between 230 and 
240°C. It absorbs maximally in UV range at 254 nm (Chee, Amirul, Muhammad, Majid, 
& Mansor, 2008). An average weight of M. speciosa leaf is about 1.7 g and a dry leaf is 
about 0.43 g, therefore, twenty leaves of M. speciosa contain approximately 17 mg of 
mitragynine (Suwanlert, 1975). However, the content of mitragynine varies between 
different geography locations. This is exemplified by differences in mitragynine content 
between M. speciosa from Malaysia and M. speciosa from Thailand whereby M. 
speciosa leaves from adult plants in Thailand have been reported to contain 
approximately over 60% mitragynine whereas those from Malaysia only contain over 
10% (Philipp, Wissenbach, Weber, Zapp, & Maurer, 2010).  
 
Besides mitragynine as the main alkaloid, other indole and oxindole alkaloids are 
also present in M. speciosa leaves. Paynantheine is the second most abundant alkaloid 
followed by speciogynine and speciociliatine (Takayama, 2004). Mitragynine and 
paynanthine appear to be exclusive to M. speciosa.  It appears that mitragynine, 
speciogynine, paynantheine with small amounts of speciociliatine are present in the 
leaves of M. speciosa (Shellard, 1974). Takayama (2004) has isolated new alkaloid 7-
hydroxymitragynine which shows profound pharmacological activity than mitragynine. 
Other minor alkaloids present in M. speciosa are corynantheidaline, corynantheidalinic 
acid, isopaynantheine, mitragynaline, mitragynalinic acid, mitraciliatine, mitraphylline, 
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rhynchophylline, speciofoline, and stipulatine (Chittrakarn, et al., 2010; Houghton, 
Latiff, & Said, 1991; Philipp, et al., 2010; Suwanlert, 1975).  
 
Report on the presence of phenolic compounds in M. speciosa is scanty. Only 
one group in US recently reported that they managed to isolate epicatechin, a flavonoids 
from M. speciosa leaves (León, et al., 2009). There is also not much report on phenolic 
compounds determined in other species of Mitragyna genus. M. rotundifolia leaves has 
been proved to contain quite a number of phenolic compounds and the phenolic 
compounds were successfully isolated. The phenolic compounds that have been isolated 
from M. rotundifolia leaves were 3,4-dihydroxybenzoic acid, caffeic acid, kaempferol,  
4’-O-methyl-gallocatechin, catechin and epicatechin (Kang, Li, & Liu, 2010). On the 
other hand, chlorogenic acid and quercetin were reported to be isolated from the stem 
bark and roots of M. inermis (Asase, et al., 2008) while scopoletic was isolated from M. 
parvifolia (Gupta, Kumar, Bansal, & Singh, 2009).  
 
2.2.4 Pharmacological Activities of Mitragyna speciosa 
Many studies have been conducted on Mitragyna speciosa leaves extracts, mitragynine 
and its derivatives for the past 44 years due to its potential pharmacologic effects in 
alleviating pain and weaning opioid addiction (Suwanlert, 1975). Suwanlert (1975) 
reported that the chronic exposure to M. speciosa elicits withdrawal symptoms in 
humans. The symptoms include irritability, yawning, rhinorrhea, myalgias, diarrhea and 
arthralgias (Suwanlert, 1975). Additionally, the developments of hyperpigmentation 
over the cheeks, anorexia, weight loss and psychosis have been described in long-term 
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M. speciosa addicts (Suwanlert, 1975). Also, chronic users of M. speciosa will develop 
tolerance, a property similar to opiates such as morphine (Pasternak, 2001; Suwanlert, 
1975). Existing consistent descriptions of clinical effects of M. speciosa stated that it is 
dose-dependent in effect; stimulant effects at lower doses, and opiate effects 
predominating at higher doses in humans (Grewal, 1932; Suwanlert, 1975).  In in vivo 
experiment, the antinociceptive effect of M. speciosa crude extract was more potent than 
its principle alkaloid alone, mitragynine (Watanabe, Yano, Horie, & Yamamoto, 1997). 
This finding indicates that minor constituents of M. speciosa other than mitragynine may 
have a very potent antinociceptive effect (Matsumoto, et al., 2004 ; Matsumoto, et al., 
2005). The minor constituent has been shown to be 7-hydroxymitragynine (Takayama, 
2004). Chittrakarn et al. (2010) reported that methanolic extract of M. speciosa leaf and 
a major alkaloid, mitragynine produced skeletal muscle relaxation with a synergistic 
effect of pancuronium and succinylcholine. Additionally, its mechanism of action was 
not only by a competitive antagonism of acetylcholine binding but also had a direct 
effect on skeletal muscle by decreasing the muscle twitch. M. speciosa extract has been 
demonstrated to stimulate Fos expression in the dorsal raphe nucleus in rats (Kumarnsit, 
Vongvatcharanon, Keawpradub, & Intasaro, 2007). Fos is a protein product of the proto-
oncogene c-fos and is used as a marker of neuronal activation (Rodella, Rezzani, Gioia, 
Tredici, & Bianchi, 1998). M. speciosa extract had an antidiarrheal effect by inhibiting 
diarrheal frequency, total diarrheal score and fecal weight. It also decreased intestinal 
transit (Chittrakarn, Sawangjaroen, Prasettho, Janchawee, & Keawpradu, 2008). This 
observation proves the utilization of M. speciosa to treat diarrhea in folk medicine. 
Kumarnsit et al. (2006) has proved that the presumed hypoglycemic activity of M. 
speciosa extract is not true. They summarized that the alkaloid extract of M. speciosa 
suppresses food and water intakes and slows weight gaining in rats and suggested that 
the suppressing effects of M. speciosa extract on food consumption might be an indirect 
mechanism that reduces the blood glucose level. M. speciosa aqueous and alkaloid 
extracts also have shown antidepressant-like effects in mouse models of behavioral 
despair tests. The study indicates that M. speciosa leaves extracts have potential to be 
used in a clinical setting (Kumarnsit, Keawpradub, & Nuankaew, 2007). 
 
Pharmacological effects of M. speciosa extract are largely due to the main 
principle alkaloid, mitragynine. A study by a group of researchers in Japan has proved 
that mitragynine acts mainly on mu and delta opioid receptor in in vitro and in vivo 
studies and possess analgesic effect (Takayama, et al., 2002; Yamamoto, et al., 1999).  
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Figure 2.2: Mitragynine Structure. 
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Mitragynine has been demonstrated to produce an antinociceptive effect through an 
action on supraspinal opioid receptor and descending noradrenergic and serotonergic 
systems which are different from morphine mechanism of action (Matsumoto, et al., 
1996; Thongpradichote, et al., 1998). Additionally, animal studies suggest that 
mitragynine may stimulate post-synaptic α2 adrenergic receptors, and/or block 
stimulation of 5-HT2A receptors (Matsumoto, et al., 2005b). Mitragynine also has been 
reported to exert morphine like action on gastric acid secretion in anesthesized rats and 
inhibits the vas deferens contraction of guinea pig elicited by nerve stimulation 
(Matsumoto, et al., 2005). Side effects of M. speciosa consumption such as anorexia and 
weight loss have been proved to be mediated by mitragynine through the stimulation of 
opioid receptors. Like morphine, stimulation of opioid receptors by mitragynine has led 
to inhibition of 2-deoxy-D-glucose-stimulated gastric acid secretion in urethane-
anesthetized rats (Tsuchiya, et al., 2002). Chronic administration of mitragynine 
significantly reduced the discrimination ratio time on object placement task where it 
shows mitragynine has impaired the cognitive function (Apryani, Hidayat, Moklas, 
Fakurazi, & Idayu, 2010). Idayu et al. (2011) have shown that administration of 
mitragynine is able to produce an obvious antidepressant-like effect in forced swim test 
and tail suspension test, which is due to interaction with neuroendocrine hypothalamic-
pituitary-adrenal axis systems (Idayu, et al., 2011). It was found that the methoxy 
functional group at C9 of mitragynine controls the maximum activity on opioid 
receptors (Matsumoto, et al., 2006; Takayama, et al., 2002). A transformation of the 
methoxy group with other chemicals group at the C9 position on mitragynine has been 
shown to drastically shift the opioid agonistic activities of mitragynine from a full 
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agonist to an antagonist of opioid receptors (Matsumoto, et al., 2006). Mitragynine 
related compounds also express interesting opioid activities especially 7-
hydroxymitragynine and mitragynine pseudoindoxyl. They are found to exhibit potent 
antinociceptive action trough the same mechanism as mitragynine via interaction with 
mu and delta opioid receptors (Matsumoto, et al., 1996). In fact, the 7-
hydroxymitragynine exhibited about 13 times higher potency than morphine and about 
46 times higher potency than mitragynine in animal studies (Matsumoto et al., 2004). On 
the other hand, mitragynine pseudoindoxy interacted with mu opioid receptor about 100 
and 20 folds higher than that of mitragynine and morphine respectively (Takayama, 
Aimi, & Sakai, 2000). It is interesting to bring out that a nitrogen atom, a benzene 
residue, and an oxygen atom, on the benzene ring in the structures of morphine and 7-
hydroxymitragynine could not superimpose using molecular modeling techniques 
(Matsumoto, et al., 2005a). The aforementioned functional groups play an important role 
in producing analgesic activity (Dhawan, et al., 1996). For that reason, it is speculated 
that 7-hydroxymitragynine binds opioid receptor sites other than those that morphine 
binds (Matsumoto, et al., 2008). Due to its unique structure and a potent activity, 7-
hydroxymitragynine may be used as a template for development of novel analgesics 
with distinct mechanisms from morphine. 
 
2.2.5 Mitragyna speciosa Legal Status 
Mitragyna speciosa leaves have been abused by drug addicts since some alkaloids 
(mainly mitragynine) from the plant posses opiate and cocaine like effects (Matsumoto, 
et al., 2004). To date, M. speciosa uses has been banned in Malaysia, Thailand, 
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Myanmar, Vietnam, Bhutan, Finland, Poland, Lithuania, Denmark and Australia due to 
its highly misuse potential. M. speciosa has been prohibited in Thailand since 1943 
whereby existing trees require to be cut down and it is illegal to buy, sell, import, 
growing and harvesting M. speciosa. Furthermore, Thailand is the only country in the 
world that classified M. speciosa in Category V of a five category classification of 
narcotics under Thai government Narcotics Act B.E. 2522, placing M. speciosa along 
with marijuana (Chittrakarn, et al., 2010). This implies the seriousness of M. speciosa 
misuse in Thailand and problems that may arise from its consumption. In Malaysia, M. 
speciosa was listed in the First Schedule and the Third Schedule (psychotropic 
substances) of the Poisons Act 1952 in August 2004 (Chan, et al., 2005). Once this act 
was enacted, individuals who possess or sell M. speciosa leaves or other M. speciosa 
preparations such as drinks and teas containing mitragynine will need to pay a penalty of 
RM 10,000, a four-year jail sentence or both (Chan, et al., 2005). More recently, the act 
is reported to be revised so that M. speciosa will be listed as a dangerous drug thus 
making the selling of it a serious drug offence. The enforcement of this law in Malaysia 
is necessary due to the escalating demand of M. speciosa extract (as concoction or tea) 
since the year 2000 as a cheap and easily available alternative of other drugs such as 
cannabis and heroin. Furthermore, there is a perception that the consumption of M. 
speciosa leads to the abuse of other drugs such as cannabis and heroin (Chan, et al., 
2005). On the contrary, M. speciosa is currently not illegal in most of the European 
Countries and in the USA. As a consequence, there is a high demand on this plant in 
these countries as a substitute for other illegal drugs (Babu, et al., 2008). Moreover, M. 
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speciosa leaves powder can be purchased online at a wide variety of shops online with 
low price (Chittrakarn, et al., 2008).  
 
2.3 Drug Metabolizing Enzymes 
Xenobiotics by definition are substances that are foreign and not nutrients for human 
body, which can enter human body through ingestion, inhalation or absorption 
(Brahmankar & Jaiswal, 1995). Once xenobiotics enter the body, they need to be 
excreted or they accumulate in the body and precipitate toxicity. On the other hand, 
drugs are any chemical substances that affect the structure or function of a living 
organism that are widely used for the prevention, diagnosis and treatment of diseases 
and for the relief of symptoms (Martin, 2007). Therefore, drugs can be regarded as 
xenobiotics that are not nutrients for the body and must be eliminated once they had 
elicited therapeutic effect or it will be accumulated and become toxic to human. There 
are two ways of drugs elimination from the body namely renal excretion and metabolism 
(Correia, 2004).  Renal excretion plays an important role in eliminating biologically 
active drugs through glomerular filtration, only if the drugs are sufficiently water 
soluble. However, this is not the case of most therapeutic drugs which need to be 
adequately lipid soluble so that it can be absorbed effectively from the gastrointestinal 
tract to systemic circulation when taken orally. This physicochemical property hinders 
the excretion of drugs via glomerular filtration since the lipophilic nature of renal 
membranes will reabsorb the drugs into the systemic circulation. Fortunately, the human 
body is armed with a set of enzymes specialized to metabolize drugs by addition of 
functional group and endogenous molecules to the drug, hence it become more polar and 
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can be excreted via the kidney. Therefore, metabolism of drugs is a chemical process 
that transform chemical from one form to another so that it can be eliminated from 
human body (Brahmankar & Jaiswal, 1995). Drug metabolizing enzymes were 
traditionally grouped into phase 1 and phase II based on the reaction it catalyzes 
(Williams, 1972). Phase I group of enzymes catalyze functionalization reactions by 
introducing, modifying or unmasking functional group such as hydroxyl (OH), amino 
(NH) and carboxylic acid (COOH). If phase I products are polar enough, they can 
directly be excreted via kidney. However, most drugs are not polar enough eventhough 
after the addition of functional groups. Therefore, phase I reaction products need to 
undergo another reaction called phase II reactions. In phase II reactions, phase II group 
of enzymes catalyze conjugation reactions by adding polar endogenous molecules such 
glucuronic acid, amino acids and glutathione which enhance the polarity of the phase I 
drug metabolites. Conjugation reactions generally result in products with total loss of 
pharmacologic activity and high polarity, hence, are better known as true detoxification 
reactions (Brahmankar & Jaiswal, 1995). 
 
Liver is the main site of drug metabolizing enzymes and it is strategically located 
between the portal vein which transports blood from the gastrointestinal tract (GIT) to 
the liver and the inferior vena cava which drains blood from liver to the heart for 
circulation to the whole body (Holt & Smith, 2008). Other organs are also capable to 
metabolize drugs to certain extent particularly lungs, kidneys, intestine, placenta, 
adrenals and skins (Brahmankar & Jaiswal, 1995). At the subcellular level, drug 
metabolizing enzymes are mainly located in the smooth endoplasmic reticulum and 
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cytosol (Correia, 2004). Route of administration of most drugs are by oral since it is the 
most convenience and easiest way (Sastry, Nyshadham, & Fix, 2000). Following oral 
administration, drugs are absorbed from the GIT to the liver via portal vein where they 
will be metabolized extensively. This process has been called as a first pass metabolism 
effect (Correia, 2004). Due to extensive metabolism in the liver, only a small portion of 
parent drug molecules can reach the blood circulation whereas the rest are in the form of 
drug metabolites. Bioavailability is the amount of parent drugs that reach blood 
circulation after undergoing a first pass metabolism effect in the liver. Therefore, the 
amounts of a parent drug that reaches the blood circulation is actually less than the 
amount taken by oral route because of metabolism make bioavailability less than 100%. 
Therefore, it could be concluded that, for most drugs, the amount of a particular drug 
that a human consumed orally is actually more than needed for a therapeutic effect. 
Nevertheless, the established oral dosages of drugs have undergone extensive research 
before they were marketed so that only a safe amount of parent drug may reach the 
blood circulation. 
 
2.3.1 Phase I Drug Metabolizing Enzymes 
Phase I drug metabolizing enzymes can catalyze oxidation, reduction and hydrolysis to 
respectively introduce new polar group, modify an existing functional group and unmask 
existing polar functional group onto a parent drug (King, 2009). Phase I drug 
metabolizing enzymes which are involved in oxidation, reduction and hydrolysis 
reactions are listed in Table 2.1. Oxidation reaction is the most common compared to the 
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other reactions. Furthermore, oxidation by cytochromes P450 is responsible for the 
metabolism of 75% of marketed drugs (Williams, et al., 2004). 
 
Table 2.1: Phase I Drug Metabolizing Enzymes which are Involved in Oxidation, 
Reduction and Hydrolysis (Gibson & Skett, 1994). 
 
Enzyme Reaction 
Cytochromes P450 Oxidation 
Alcohol dehydrogenase Oxidation
Aldehyde dehydrogenase Oxidation
Xanthine oxidase Oxidation
Aldo/keto reductase Reduction 
NADPH quinone oxidoreductase Reduction
Carbonyl reductase Reduction
Acetylcholinesterase Hydrolysis 
Carboxylesterase Hydrolysis
Aminopeptidase Hydrolysis
 
2.3.1 (a) Cytochrome P450 
Cytochrome P450, CYP450 (EC 1.14.14.1) belong to a superfamily of heme-containing 
enzymes with more than 4000 members (Urlacher & Eiben, 2006). CYP450 derived its 
name from the peculiar difference spectrophotometric absorbance peak unlike typical 
hemoprotein at 450 nm when reduced by a reducing agent and bound by carbon 
monoxide (Omura & Sato, 1964). CYP450 is the primary enzymes catalyzing the 
oxidations of a variety of endogenous and exogenous chemicals including steroids, 
drugs, and chemical carcinogens (Guengerich, 1992). Table 2.2 lists the type of 
oxidation reactions that CYP450 may catalyze for a particular drug. Additionally, 
CYP450 are responsible for metabolizing almost 75% of top 200 marketed drugs in the 
USA (Williams, et al., 2004). 
 
Table 2.2: Type of Oxidation Reaction Catalyzed by CYP450 (Gibson & Skett, 1994). 
Drug Type of Oxidation Reaction 
Lignocaine Aromatic hydroxylation 
Pentobarbitone Aliphatic hydroxylation 
Diazepam N-Dealkylation
Codeine O-Dealkylation
Amphetamine Oxidative deamination 
Chlorpromazine O-Dealkylation
Halothane Dehalogenation
Ethanol Alcohol oxidation 
 
CYP450 introduced functional groups onto drug molecules by insertion of atomic 
oxygen from molecular oxygen into a substrate with the simultaneous reduction of the 
other atom to water (Bernhardt, 2006) like the following reaction: 
 
RH + O2 + NADPH + H+  ?  ROH + H2O + NADP+ 
 
This reaction requires CYP450, NADPH-cytochrome P450 reductase and phospholipids. 
The system is collectively known as mixed function oxidase or monooxygenase. The 
reductase is responsible for the transfer of two electrons from NADPH to CYP450. The 
electrons caused oxidoreduction reaction on CYP450 which split the molecular oxygen. 
In this case, one oxygen atom will be inserted into drugs and the other oxygen atom is 
reduced to water (Uetrecht & Trager, 2007). 
 
All CYP450 carry a CYP prefix to show that they are the members of the 
cytochrome P450 superfamily. Human CYP450 can be grouped into several families 
depending on the similarity of their gene sequences. Enzymes with more than 40% 
sequence similarity are assigned to the same family, while those with more than 55% are 
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